Melanoma and Skin Cancer Trials Limited clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 1 with a minor change only.

1. Notable

   BETTER · Bevacizumab and ICIs + hSRT in Symptomatic Melanoma…BETTER · Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

   Primary completion pushed from Jan 30, 2026 to Jan 30, 2028

   Also in this update: Study completion pushed from Jan 30, 2026 to Jan 30, 2030

   Melanoma and Skin Cancer Trials Limited·Phase 1/2· NCT06163820· Registry history of NCT06163820 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

2. Notable

   NEOPECS · Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in…NEOPECS · Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

   Primary completion pushed from Jul 30, 2026 to Jul 30, 2030

   Melanoma and Skin Cancer Trials Limited·Phase 2· NCT06418724· Registry history of NCT06418724 on ClinicalTrials.gov (opens the registry)

   Oct 7, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.